• Mashup Score: 0
    Home | Fierce JPM Week - 2 year(s) ago

    We might have thought the COVID-19 pandemic would be over by year-end 2021, but experts now say—and the omicron variant suggests—the virus will likely always be with us. What pandemic lessons has the industry learned that can help tackle longtime challenges—such as speeding up drug development, adding new diversity into clinical trials, launching new products and, of course,…

    Tweet Tweets with this article
    • The #JPM22 conversations continue this week with our virtual #FierceJPMWeek Jan. 18-20. Find the lineup and sign up here: https://t.co/ZDeKBKHoee

  • Mashup Score: 0
    Home | Fierce JPM Week - 2 year(s) ago

    We might have thought the COVID-19 pandemic would be over by year-end 2021, but experts now say—and the omicron variant suggests—the virus will likely always be with us. What pandemic lessons has the industry learned that can help tackle longtime challenges—such as speeding up drug development, adding new diversity into clinical trials, launching new products and, of course,…

    Tweet Tweets with this article
    • The #JPM22 conversations continue this week with our virtual #FierceJPMWeek Jan. 18-20. Find the lineup and sign up here: https://t.co/IWlWdtkAI0

  • Mashup Score: 1
    Home | Fierce JPM Week - 2 year(s) ago

    We might have thought the COVID-19 pandemic would be over by year-end 2021, but experts now say—and the omicron variant suggests—the…

    Tweet Tweets with this article
    • #FierceJPMWeek is here! Tomorrow's stacked lineup includes a panel on trial diversity, an executive interview with Bayer AG's head of R&D and lots more. Sign up now (it's free!): https://t.co/qKxY8ScNYT